D
Daniel Aletaha
Researcher at Medical University of Vienna
Publications - 398
Citations - 51111
Daniel Aletaha is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 74, co-authored 298 publications receiving 43215 citations. Previous affiliations of Daniel Aletaha include National Institutes of Health & University of Vienna.
Papers
More filters
Journal ArticleDOI
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022
Kevin L. Winthrop,John D. Isaacs,Philip J. Mease,Dimitrios T. Boumpas,Xenofon Baraliakos,Jacques-Eric Gottenberg,Stefan Siebert,Marta Mosca,Neil Basu,Dana E. Orange,Rju Lories,Daniel Aletaha,Iain B. McInnes,Tom W J Huizinga,Reinhard E. Voll,Ellen M. Gravallese,F. C. Breedveld,Josef S Smolen +17 more
TL;DR: The 22nd annual Advances in Targeted Therapies meeting brought together more than 100 leading basic scientists and clinical researchers in rheumatology, immunology, epidemiology, molecular biology and other specialties as mentioned in this paper .
Journal ArticleDOI
ACR Convergence 2022 Abstract Supplement.
Daniel Mrak,Felix Kartnig,Daniela Sieghart,Helga Radner,Peter Mandl,L. Goschl,Peter Hofer,Tourtellotte Hummel,Thomas Deimel,Irina Gessl,Robert R. Kain,S Winkler,Jim J. Smolen,Thomas Perkmann,Daniel Aletaha,Leitner Karl Heinz,Maddalena Bonelli +16 more
TL;DR: For a searchable version of these abstracts, please visit www.acrabstracts.org as mentioned in this paper , where the abstracts are linked to the corresponding abstracts of the paper.
Journal ArticleDOI
Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis
TL;DR: Clinical responses to placebo are higher in patients who continue an insufficient MTX background therapy, which suggests an inadvertently more consequent intake of background therapy during the trial.
Journal ArticleDOI
Considering new lessons about the use of IL-6 inhibitors in arthritis
Tsutomu Takeuchi,Josef S Smolen,Ernest Choy,Daniel Aletaha,Iain B. McInnes,Simon Arnett Jones +5 more
TL;DR: In addition to the different blocking actions of monoclonal antibodies, therapeutic strategies including the timing of IL-6 blockade and the use of monotherapy versus the addition of methotrexate are considered.
Journal ArticleDOI
Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis.
Josef S Smolen,Daniel Aletaha +1 more
TL;DR: This Viewpoint discusses approaches to comprehensive reviews in general and to those involving rheumatoid arthritis in particular, from the clinical trialist's point of view.